Current treatment approaches for breast cancer patients with HER2-positive disease in the adjuvant, and neo-adjuvant setting

Breast cancer (BC) is the second most common and leading cause of mortality among women globally. Approximately 20% to 25% BC patients have amplification human epidermal growth factor receptor 2 (HER2) genes, a marker poor prognosis. However, introduction anti-HER2- therapies (trastuzumab, followed closely by lapatinib, pertuzumab, T-DM 1) has changed natural history HER2-positive improved prognosis survival in patients. The approval trastuzumab pertuzumab linked with taxane as first-line treatment follow-up antibody-drug conjugate T-DM1 undeniably contributed attaining these outcomes. Tyrosine Kinase Inhibitor lapatinib another commonly used combination capecitabine, approved on basis an improvement progression-free survival. superiority anti-HER2 therapy achieve more complete inhibition various HER dimers been demonstrated clinical studies. Nonetheless, studies also suggested that some HER2-amplified tumors may benefit from combined only single chemotherapy agent or absence any chemotherapy. despite therapeutic advances, expressing estrogen (ER) poorer responses targeted are likely relapse. A better understanding resistance existing agents, along role played microenvironment interconnected signaling pathways, can permit tailor-made options for each patient. aim this review evaluate approaches disease adjuvant, neoadjuvant setting.